# melanotan: a cyclic alpha-MSH analog studied across four research domains from 1989 to 2026 > melanotan: two synthetic alpha-MSH analogs studied for pigmentation, erectile function, appetite, and neuroprotection across thirty years of published literature. Primary findings indexed. ## What Is Melanotan? melanotan refers to two synthetic peptide analogs of alpha-melanocyte-stimulating hormone (alpha-MSH): Melanotan I (afamelanotide, a linear 13-amino-acid analog) and Melanotan II (a cyclic 7-amino-acid analog). Both were developed at the University of Arizona by Hruby and Hadley beginning in the late 1980s as truncated, cyclized, enzymatically resistant derivatives of the endogenous alpha-MSH tridecapeptide [1]. The original research rationale was photoprotection: if a synthetic alpha-MSH analog could drive melanin production in human skin, it might reduce UV-induced DNA damage and lower skin cancer incidence [1]. That rationale produced three decades of published research, two approved compounds (afamelanotide for erythropoietic protoporphyria; bremelanotide/PT-141 for hypoactive sexual desire disorder), and a persistent unapproved compound — Melanotan II — still studied but approved nowhere [2]. Melanotan II binds non-selectively to melanocortin receptors 1, 3, 4, and 5 (MC1R–MC5R). MC1R activation drives melanogenesis — the cAMP/PKA/CREB/MITF cascade that upregulates tyrosinase and shifts melanin synthesis toward the darker eumelanin form [4]. MC4R activation in the central nervous system mediates appetite suppression, the erectogenic effect, and the autonomic side effects (nausea, yawning) observed in early human trials [5][6][7]. ## Melanotan II vs. Melanotan I: How the Two Analogs Differ Melanotan I (afamelanotide) is a linear 13-amino-acid analog with preferential MC1R selectivity. Melanotan II is a cyclic 7-amino-acid heptapeptide (Cyclo(His-Phe-Arg-Trp-Gly), MW 1024.2 Da) with broader MC1R/MC3R/MC4R/MC5R activity. The cyclization of MT-II improved its metabolic stability and receptor potency relative to MT-I [2]. MT-I's MC1R selectivity made it a clean photoprotection candidate. EU approval (Scenesse, 2014) and FDA approval (2019) followed for erythropoietic protoporphyria [15]. MT-II's broader receptor activity produced measurable erectogenic and anorexigenic effects. MT-II itself has no approved indication in any jurisdiction. ## What Is Melanotan Made Of? Melanotan II is a fully synthetic peptide produced by solid-phase peptide synthesis from standard amino acid precursors. Molecular weight: 1024.2 Da [1]. Oral bioavailability in rats is 4.6%; subcutaneous injection is the standard research route [1]. ## Research Applications of Melanotan II - **Pigmentation and melanogenesis.** Phase I data showed measurable pigmentation increases in human subjects without UV exposure [3]. The MC1R → cAMP/PKA/CREB/MITF/tyrosinase cascade is well established [4]. - **Erectile dysfunction.** Two double-blind, placebo-controlled crossover trials in psychogenic and organic ED demonstrated erectogenic effects at 0.025 mg/kg subcutaneous [5][6][7]. - **Appetite suppression.** Rodent ICV studies showed anorexic effects and adiposity reduction via MC4R [8][9][10]. - **Neuroprotection.** MT-II at 20 µg/kg subcutaneous promoted peripheral nerve regeneration in a rat sciatic crush model with bell-shaped dose-response [21]. ## Melanotan II Research in Male Subjects Three human trials enrolled male subjects. In the 1996 pilot Phase I study, 3 healthy males received 5 low-dose injections (0.01–0.03 mg/kg/day); measurable pigmentation increases appeared in 2 of 3, and spontaneous penile erections lasting 1–5 hours post-injection were an incidental finding [3]. A 1998 double-blind crossover trial in 10 men with psychogenic ED found 0.025 mg/kg produced erections in 8 of 10 subjects; mean tip rigidity >80% lasted 38 minutes vs. 3 minutes for placebo (p=0.0045) [5]. A 2000 trial in 20 men with organic ED: 17 of 20 subjects had erections; increased sexual desire followed 68% of active doses vs. 19% of placebo [6]. A second 2000 trial in 10 men confirmed erection duration ~45 minutes with active drug vs. 1.9 minutes for placebo [7]. ## References [1] Lan EL et al. Preformulation studies with melanotan-II. J Pharm Sci. 1994. PMID: 7983590 [2] Hadley ME, Dorr RT. Melanocortin peptide therapeutics. Peptides. 2006. PMID: 16412534 [3] Dorr RT et al. Evaluation of melanotan-II in a pilot phase-I clinical study. Life Sci. 1996. PMID: 8637402 [4] Hida T et al. Elucidation of Melanogenesis Cascade. Int J Mol Sci. 2020. PMID: 32854423 [5] Wessells H et al. Synthetic melanotropic peptide initiates erections. J Urol. 1998. PMID: 9679884 [6] Wessells H et al. Melanocortin receptor agonists, penile erection. Int J Impot Res. 2000. PMID: 11035391 [7] Wessells H et al. Effect of alpha-MSH analog on penile erection. Urology. 2000. PMID: 11018622 [8] Zhang Y et al. Intermittent MTII application evokes repeated anorexia. Peptides. 2010. PMID: 20034526 [9] Cote I et al. Activation of the central melanocortin system. Can J Physiol Pharmacol. 2017. PMID: 28051332 [10] Eliason NL et al. Melanotan-II microinjected in nucleus accumbens. Neuropeptides. 2022. PMID: 36155088 [15] Langendonk JG et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015. PMID: 26132941 [19] Hadley ME, Dorr RT. Melanocortin peptide therapeutics (PT-141). Peptides. 2006. PMID: 16412534 [21] Ter Laak MP et al. Melanotan-II promotes peripheral nerve regeneration. Eur J Pharmacol. 2003. PMID: 12591111 --- A drill-down index of the peer-reviewed melanotan record — Phase I trials, preclinical mechanism studies, and documented adverse events, cited to the source.